Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex Corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
10.21
2014
Addex and the Charcot-Marie-Tooth Association enter collaboration to advance ADX71441 in Charcot-Marie-Tooth 1A disorder
09.30
2014
Addex Therapeutics Reports First Half 2014 Financial Results
07.10
2014
Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction
06.30
2014
Addex Shareholders Approve All Board Proposals at Annual General Meeting
06.12
2014
Addex Therapeutics Publishes Annual General Meeting Agenda
05.30
2014
Addex Therapeutics Publishes Annual Report 2013
04.30
2014
Addex Therapeutics Reports 2013 Financial Results
02.07
2014
Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms
11.04
2013
Addex and NIDA enter collaboration to advance ADX71441 & ADX88178 in drug abuse and addiction
10.29
2013
Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back